OVERVIEW

Addressing Bone Manifestations of GD: The Latest Evidence in Evaluation and Treatment is organized by Med-IQ and will be held from Oct 10, 2018 - Oct 09, 2019.

Target Audience:
This activity is intended for genetic counselors, geneticists, and hematologists.

Accreditation/Designation Statements:
Med-IQ designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medium/Method of Participation
This CME activity consists of a 1.0-credit online publication. To receive credit, read the introductory CME material, read the publication, and complete the post-survey, evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.

Conference Description:
This accredited CME publication explores bone manifestations of Gaucher disease (GD) and includes video clips of expert faculty discussing key clinical considerations and patient case examples. Clinical evidence for GD treatment is also presented.

Statement of Need:
The majority of patients with type 1 GD experience bone manifestations, which can be associated with intense pain, impaired mobility, and reduced quality of life. Recent evidence has provided new insight in diagnosing and monitoring bone disease progression. In addition, clinical trials have shown that enzyme replacement therapy (ERT) and substrate reduction therapy (SRT) may be beneficial for mitigating bone-related complications of GD. As data regarding the genetics, biochemistry, and pathophysiology of GD-related bone manifestations continue to emerge, clinicians, researchers, and geneticists need to be aware of advances in the clinical evidence and the application of that knowledge to the care of patients with GD.

Learning Objectives:
Upon completion, participants should be able to:
• Recognize the relationship between bone physiology and GD
• List the diagnostic tools critical for the identification of bone involvement in GD
• Determine appropriate GD treatment strategies for patients with bone-related GD manifestations.